Johanna Mercier
Chief Commercial and Corporate Affairs Officer, Gilead Sciences
In the news
Gilead agrees to buy Arcellx for $115 per share in cash plus CVR, about $7.8 billion
Gilead agreed to acquire the rest of Arcellx, the partner on anito-cel, a BCMA-directed CAR T-cell therapy for multiple myeloma.
M&A